ATTR Amyloidosis – Pipeline Insight, 2020
![](/report_cover/8047/attr-amyloidosis-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “ATTR Amyloidosis – Pipeline Insight, 2020,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ATTR Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ATTR Amyloidosis: Overview
ATTR Amyloidosis is a disorder of protein misfolding. Normally, liver made Transthyretin (TTR) proteins is made up of four identical parts and helps in carrying of thyroid hormone and vitamin A in the blood. However, in ATTR amyloidosis, the protein becomes unstable, breaks apart, and deposits in the heart and/or the nerves. ATTR amyloidosis can be either hereditary or acquired (non-hereditary). Hereditary ATTR amyloidosis is caused due to inheritance of mutated DNA while in Wild-type ATTR amyloidosis, normal TTR protein becomes unstable, misfolds and forms amyloid fibrils.
Symptoms
The symptoms of ATTR Amyloidosis depends on the organ involved and include:
A diagnosis of ATTR Amyloidosis is based upon patients’ symptoms, findings on physical examination and sometimes family history. The diagnosis can be confirmed (or eliminated) by certain tests like Tissue biopsy, Genetic testing, and Imaging studies.
Treatment
The goals for ATTR amyloidosis treatment is to stop disease progression by limiting TTR deposits, and minimize the effects that ATTR has on your body. The specific therapeutic treatment used depend upon several factors, including the severity of the disorder. Therapies that are used to treat ATTR Amyloidosis are focused on principles like Small interfering RNA and Antisense oligonucleotides.
ATTR Amyloidosis Emerging Drugs Chapters
This segment of the ATTR Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATTR Amyloidosis Emerging Drugs
Further product details are provided in the report
ATTR Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different ATTR Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
ATTR Amyloidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ATTR Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATTR Amyloidosis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “ATTR Amyloidosis – Pipeline Insight, 2020,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ATTR Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ATTR Amyloidosis: Overview
ATTR Amyloidosis is a disorder of protein misfolding. Normally, liver made Transthyretin (TTR) proteins is made up of four identical parts and helps in carrying of thyroid hormone and vitamin A in the blood. However, in ATTR amyloidosis, the protein becomes unstable, breaks apart, and deposits in the heart and/or the nerves. ATTR amyloidosis can be either hereditary or acquired (non-hereditary). Hereditary ATTR amyloidosis is caused due to inheritance of mutated DNA while in Wild-type ATTR amyloidosis, normal TTR protein becomes unstable, misfolds and forms amyloid fibrils.
Symptoms
The symptoms of ATTR Amyloidosis depends on the organ involved and include:
- Carpal tunnel syndrome.
- Numbness, burning and/or tingling (peripheral neuropathy).
- Biceps tendon rupture.
- Lumbar spinal stenosis.
- Swelling of the feet or legs.
- Eye floaters (vitreous opacities).
- Shortness of breath.
- Palpitations.
- Chest pain.
- Diarrhea or constipation.
A diagnosis of ATTR Amyloidosis is based upon patients’ symptoms, findings on physical examination and sometimes family history. The diagnosis can be confirmed (or eliminated) by certain tests like Tissue biopsy, Genetic testing, and Imaging studies.
Treatment
The goals for ATTR amyloidosis treatment is to stop disease progression by limiting TTR deposits, and minimize the effects that ATTR has on your body. The specific therapeutic treatment used depend upon several factors, including the severity of the disorder. Therapies that are used to treat ATTR Amyloidosis are focused on principles like Small interfering RNA and Antisense oligonucleotides.
ATTR Amyloidosis Emerging Drugs Chapters
This segment of the ATTR Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATTR Amyloidosis Emerging Drugs
- Acoramidis - Eidos Therapeutics
- AKCEA-TTR-LRx: Ionis Pharmaceuticals
Further product details are provided in the report
ATTR Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different ATTR Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in ATTR Amyloidosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
ATTR Amyloidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ATTR Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATTR Amyloidosis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ATTR Amyloidosis R&D. The therapies under development are focused on novel approaches to treat/improve ATTR Amyloidosis.
- ATTR Amyloidosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing ATTR Amyloidosis drugs?
- How many ATTR Amyloidosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ATTR Amyloidosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ATTR Amyloidosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ATTR Amyloidosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eidos Therapeutics
- Ionis Pharmaceuticals
- Alnylam Pharmaceuticals
- Intellia Therapeutics
- Prothena
- Corino Therapeutics
- SOM Biotech
- Neurimmune Therapeutics
- Acoramidis
- AKCEA-TTR-LRx
- Vutrisiran
- NTLA-2001
- PRX004
- Tolcapone
- Revusiran (ALN-TTRSC)
- NI-006
Introduction
Executive Summary
ATTR Amyloidosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ATTR Amyloidosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ATTR Amyloidosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ATTR Amyloidosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Acoramidis - Eidos Therapeutics
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Revusiran: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
NTLA-2001: Intellia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
ATTR Amyloidosis Key Companies
ATTR Amyloidosis Key Products
ATTR Amyloidosis- Unmet Needs
ATTR Amyloidosis- Market Drivers and Barriers
ATTR Amyloidosis- Future Perspectives and Conclusion
ATTR Amyloidosis Analyst Views
ATTR Amyloidosis Key Companies
Appendix
Executive Summary
ATTR Amyloidosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ATTR Amyloidosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ATTR Amyloidosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ATTR Amyloidosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Acoramidis - Eidos Therapeutics
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Revusiran: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
NTLA-2001: Intellia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
ATTR Amyloidosis Key Companies
ATTR Amyloidosis Key Products
ATTR Amyloidosis- Unmet Needs
ATTR Amyloidosis- Market Drivers and Barriers
ATTR Amyloidosis- Future Perspectives and Conclusion
ATTR Amyloidosis Analyst Views
ATTR Amyloidosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for ATTR Amyloidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ATTR Amyloidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for ATTR Amyloidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for ATTR Amyloidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products